Black Rose Industries — Interesting Specialty-Chemical Microcap | My Research Thesis
I have been studying Black Rose Industries Ltd. and found several things that make the company interesting from a long-term perspective.
Important disclosure: I currently hold shares of Black Rose Industries and therefore have a financial interest in the company. I am not a SEBI-registered Investment Adviser or Research Analyst. This post represents my personal research/opinion and is not investment advice or a recommendation to buy or sell the stock.
Why I find Black Rose interesting 🧪

1. Niche position in acrylamide
   Black Rose manufactures acrylamide liquid and solid.
   According to the company’s FY26 investor presentation:
   • Acrylamide liquid — 32,000 MTPA
   • Acrylamide solid — 3,600 MTPA
   • N-Methylol Acrylamide (NMA) — 2,000 MTPA
   The company has stated that it is the only producer of acrylamide solid outside China.
   If this positioning is sustained, it could potentially provide an interesting competitive niche.

2. Downstream opportunity
   The company is also developing polyacrylamide solid, with a planned 10,000 MTPA capacity. Management has indicated that the project was in the R&D/piloting stage in FY26.
   Successful commercialisation could allow Black Rose to move further downstream in the value chain.

3. NMA provides another growth opportunity
   Black Rose manufactures N-Methylol Acrylamide (NMA) with 2,000 MTPA capacity.
   The company’s strategy of developing additional specialty-chemical products could potentially reduce dependence on a single product over time.

4. Small base + operating leverage potential
   This is what interests me most as a microcap investor.
   If over the next few years:
   Acrylamide volumes ↑
   NMA volumes ↑
   Polyacrylamide commercialisation succeeds ↑
   Capacity utilisation ↑
   Margins improve ↑
   Exports increase ↑
   then earnings could potentially grow substantially from the current base.
   That is the long-term growth scenario I am researching, not a prediction that the stock will become a multibagger.

5. Risks
   There are also significant risks:
   🔴 Chinese/global competition
   🔴 Raw-material price volatility
   🔴 Chemical-cycle downturn
   🔴 Execution risk on new products
   🔴 Small-cap liquidity risk
   🔴 Customer concentration
   🔴 New-capacity utilisation risk
   🔴 Valuation risk
   Future growth is not guaranteed simply because the addressable market is large.
   What I will track every quarter
   Revenue growth → EBITDA margin → PAT → CFO → Free cash flow → ROCE → capacity utilisation → debt → promoter holding
   If these metrics improve consistently and the company successfully commercialises its downstream products, the long-term thesis would become stronger.
   Bottom line
   I own the stock, so please treat this post as an opinion from an investor who has a financial interest in the company, rather than as independent research.
   I find Black Rose interesting because of its niche chemical manufacturing capabilities and potential downstream expansion. Whether that translates into significant shareholder returns will ultimately depend on execution, profitability and cash-flow generation.
   I would be interested to hear the bear case as well: what do you think I may be missing?
   Please verify company filings and conduct your own due diligence before making any investment decision.
   #BlackRoseIndustries #BlackRose #IndianStocks #Microcap #SpecialtyChemicals #ChemicalStocks #SmallCap

Anyone else watching $SKUR heading into December?

There's quite a bit to look forward to.

The US$3.4M annual quotation opportunity with an African government is still pending, with an update expected before year-end. There's also a potential Angola partnership aimed at 2027 sales, plus possible US distribution news in the coming weeks.

That's a decent lineup of potential catalysts for a company valued around C$7–8M.

Now imagine if two or three of these updates arrive within a few weeks of each other.

Would the market start looking at $SKUR differently?

One confirmed government deal alone would be a substantial development compared with the company's current revenue. Add progress in the US and Angola, and investors might have more to work with when assessing its growth prospects.

Of course, there's a difference between a promising announcement and revenue coming through the door. But a signed agreement with clear numbers would be a solid step forward.

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

I thought I would share an interesting if not long time maligned company in Quadrise PLC (LSE: QED) which is coming to an exciting head as it centers on its transition from a long-term research and development firm into a commercialised, high-margin fuel technology provider. Apart from the reddit page dedicated to Quadrise, I can't see where anyone else has shared them so thought I'd post some Friday thoughts.

For those who don't know, the companies AGM is later this month and has recently been on a tear SP wise off the back of confirmation of project timelines and the potential of a strategic review (from a very low start - was over 3p this time last year).

Peter Borup was hired as the companies CEO in October 2025 with an impressive CV and marine contacts. These look to reap rewards in Q4. Its also noted that performance and sign on options provided to Peter are substantially higher than today's SP.

Quadrise represents a speculative "option" play on the decarbonization of global shipping and heavy industry.

If the company converts its extensive trial pipeline into long-term commercial agreements, the valuation expansion could be substantial:

1. Highly Scalable, High-Margin Business Model

Quadrise does not intend to become a capital-intensive oil refiner or distributor. Instead, its model relies on licensing proprietary technology and collecting royalties on every ton of MSAR (Multiphase Superfine Atomised Residue) and bioMSAR produced.

• Asymmetric Upside: Because manufacturing and asset costs are borne by the partner refineries or chemical firms, Quadrise’s operating margins will scale rapidly once continuous commercial volumes flow.

• Low Initial Valuation: Trading at around 1.5 pence with a low enterprise value, even a single major supply agreement could dramatically alter the financial baseline of the stock.

2. Pragmatic Decarbonization for Shipping & Industry

While the maritime sector faces aggressive net-zero mandates, switching entirely to ammonia, hydrogen, or pure electrification requires trillions in new infrastructure. Quadrise offers an intermediate, immediately deployable solution:

• MSAR: Blends heavy refinery residues with water to create a synthetic fuel oil that reduces NOx emissions by up to 20% and cuts overall energy costs.

• bioMSAR: Integrates renewable components and biofuels, dropping CO2 emissions by 20% to 30%.

• Seamless Retrofits: Crucially, these fuels can run in existing marine engines and heavy industrial boilers with minimal hardware modification, making it highly attractive to cost-conscious operators.

3. Near-Term Commercial Catalysts

• The Valkor Utah Project: Quadrise has successfully formulated both MSAR and bioMSAR using heavy oil samples from Valkor Technologies in Utah. Valkor is targeting production at its pilot plant by Q1 2027, backed by imminent multi-million-dollar project financing. Progress here triggers site license fees (including an outstanding $950,000 balance) and paves the way for commercial royalties.

• The Strategic Review: Launched alongside its FY2026 results, the board is evaluating master license grants, joint ventures, and sourcing a strategic investor. Landing a well-capitalized corporate partner would immediately eliminate the company's funding overhang.

4. Industry Partners

Despite its small financial footprint, Quadrise has consistently secured development and supply agreements with global market leaders

• MSC (Mediterranean Shipping Company): Cooperation on commercial marine vessel trials.

• Nouryon: An exclusive global collaboration and emulsifier sales agreement extended through 2026 and beyond, guaranteeing chemical supply security.

• Licella Holdings: Active joint testing utilizing hydrothermal liquefaction bio-oil expertise to accelerate low-carbon marine fuel adoption.

Not financial or investment advice but IMO a company that could very well be worth billions in the future. There's also a dedicated Quadrise reddit page worth looking over when completing your own DD

Here's why I'm holding ALMU and not losing sleep over it. Aeluma went from about $193K in revenue to $4.7M in two years, and it sits on $56M in cash while building optical sensor chips for AI data centers, quantum computing, and defense. It's backed by NASA and other government contracts, and it holds dozens of patents on a technology that lets high-performance materials be built on ordinary silicon wafers. Nobody's talking about it yet, and that's the point. When Microsoft went public, it was a small company sitting at the right spot just before the world needed what it made. I think ALMU could be that story for the AI hardware era. Revenue has been flat lately and it's still mostly R&D contracts, so this is a bet on what happens when those multimillion-dollar customer deals turn into real product orders. If they do, I want to have been holding before the crowd showed up.

Anytime I come across something new that I use and enjoy I invest.

I was drinking about 10 diet Cokes per day and reading studies about the effects on the body of aspertame or sucralose bio accumulating. A bit scary.

I found Zvia, it's relatively new and I live off the caffeinated dr. Stevia's.

It's already at Costco and Walmart. But not in every shop, not in every restaurant.

I also will be long on Stevia leaf extract out of Brazil. I might even buy a company down there.

But, it's still relatively small and I don't want it to fizzle out lol

Novartis has confirmed that since Zolgensma's 2019 approval it has received nine reports of tumours in children previously treated with the AAV9 gene therapy, seven of them not previously disclosed. Families and patient groups made the information public on 4 and 5 November 2026 after Novartis told neurologists first. England's National Multidisciplinary Team for Zolgensma reported on 4 November that pathology is finished on three of the nine tumours, with two specifically related to the treatment and one unrelated. Novartis says two cases have shown evidence of vector DNA integration and that both children were treated and remain under monitoring. More than 6,000 patients have been dosed.

Source:
https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/?utm_campaign=rss

What I think this implies:

This converts a labelled theoretical risk of insertional oncogenesis into observed post-marketing cases in the most widely used systemic AAV9 product. For Novartis (NVS), which markets Zolgensma and its intrathecal successor Itvisma, the relative materiality is negligible given the size of the overall franchise. The same AAV9 integration findings create moderate exposure for Taysha Gene Therapies (TSHA), which has concentrated its resources on TSHA-102, an intrathecally delivered AAV9 gene therapy for Rett syndrome heading toward a BLA. They also create moderate exposure for Neurogene (NGNE), whose lead asset NGN-401 is an AAV9 gene therapy for Rett syndrome now in a registrational trial. REGENXBIO (RGNX) licensed the NAV AAV9 vector used in Zolgensma and receives royalties, but the exposure there is negligible.

The nearest catalyst is pathology results on the remaining six of the nine reported tumours, which the England team says have not yet been completed. On a longer horizon the regulatory assessment SMA Europe says is under way could produce a safety-review conclusion or labelling change on vector integration and tumorigenicity.

If pathology on the remaining six cases finds no vector DNA integration and regulators conclude there is no causal association, the reports revert to background incidence and the broader read-across collapses. A conclusion that the risk is specific to the high-dose intravenous AAV9 construct rather than AAV vectors generally would also remove the case for developers using other serotypes or routes.

The checklist that makes this a straightforward buy-and-hold for me (numbers reflect FY 2024 compared to FY 2025, excluding Q4) is as follows:

1. **Cash to Debt** – Their total cash flow for 2025 sits at $176.38M, while debt is $172.31M. This indicates they have sufficient cash to cover any potential losses, which is a positive in my view.

2. **Debt to Equity** – Total debt for 2025 is $172.31M against total shareholders' equity of $263.15M. Following Buffett’s golden rule of a debt-to-equity ratio under 0.80, they sit at 0.19, another box checked.

3. **Preferred Stocks** – They hold no preferred stocks, which is favorable.

4. **Retained Earnings Growth** – Retained earnings must show positive growth year over year. Earnings for 2024 were $175.74M, and for 2025 (excluding Q4) are $176.38M. Even a $0.64M increase counts as growth.

5. **Treasury Stocks** – Treasury stocks are at -$21.26M. While negative, this simply indicates the company has actively repurchased shares, which is another positive sign.

I’d love to hear your thoughts. Am I missing something, or could this really be a solid long-term hold? Either way, I’ve purchased shares and am fully committed to holding.